Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31510341 | 0.98 | GNAO1 (0.44) | SIGMAR1GNAO1GNAI3GNAI1FFAR4 | |
| SCHEMBL17526971 | 0.93 | GNAO1 (0.49) | SIGMAR1GNAO1GNAI3GNAI1FFAR4 | |
| SCHEMBL17526841 | 0.93 | GNAO1 (0.49) | SIGMAR1GNAO1GNAI3GNAI1FFAR4 | |
| SCHEMBL17526458 | 0.90 | GNAO1 (0.45) | SIGMAR1GNAO1GNAI3GNAI1HRH2 | |
| SCHEMBL17526509 | 0.90 | GNAO1 (0.45) | SIGMAR1GNAO1GNAI3GNAI1HRH2 | |
| SCHEMBL17526616 | 0.88 | GNAO1 (0.47) | SIGMAR1GNAO1GNAI3GNAI1FFAR4 | |
| SCHEMBL17526676 | 0.88 | GNAO1 (0.47) | SIGMAR1GNAO1GNAI3GNAI1FFAR4 | |
| SCHEMBL15187332 | 0.88 | SIGMAR1 (0.43) | SIGMAR1GNAO1GNAI3GNAI1HRH2 | |
| SCHEMBL15187325 | 0.88 | SIGMAR1 (0.43) | SIGMAR1GNAO1GNAI3GNAI1HRH2 | |
| SCHEMBL11039479 | 0.84 | SMN1; SMN2 (0.50) | SIGMAR1GNAO1GNAI3GNAI1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642262-B2 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-0958280-B1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-6838470-B2 | Arylpiperidinopropanol and arylpiprazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1138678-B1 | Process for making N-((4-phenyl) methylphenyl) piperazines | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6525199-B1 | Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases | SUNTORY LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-6525199-B1 | Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases | SUNTORY LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-6407099-B1 | SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2002-06-18 | — | — | US | disclosed |
| US-6407099-B1 | SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1138678-A2 | Process for making N-((4-phenyl) methylphenyl) piperazines | SUNTORY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| EP-0958280-A1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999023072-A1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, APOL1 | SIGMAR1 351/4885GNAO1 1009/4885GNAI3 3162/4885 |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, NR3C2 | SIGMAR1 464/4885GNAO1 1022/4885GNAI3 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.